Briacell Therap (NASDAQ:BCTX) Shares Up 1.1% – What’s Next?

Briacell Therap (NASDAQ:BCTX) shares shot up 1.1% during mid-day trading on Tuesday . The stock traded as high as $3.65 and last traded at $3.63. 109,117 shares were traded during trading, a decline of 83% from the average daily volume of 623,734 shares. The stock had previously closed at $3.59.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Briacell Therap presently has a consensus rating of “Sell”.

Briacell Therap Price Performance

The firm has a market cap of $31.58 million, a price-to-earnings ratio of -0.46 and a beta of 1.09. The business has a fifty day simple moving average of $3.55 and a 200 day simple moving average of $3.74.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings results on Tuesday, June 9th. The company reported ($0.99) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new position in Briacell Therap stock. Citadel Advisors LLC bought a new stake in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors and hedge funds.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.